Trial Profile
A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subject with Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 20 May 2021 Results of post-hoc analyses evaluating relationship of SF-12 as an outcome measure of HRQOL in patients with schizophrenia, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 25 Sep 2020 According to an Janssen media release, the company has obtained approval of paliperidone palmitate (Zeprion TRI) Suspension Intramuscular long-acting injection with a 12-week interval in Japan for the treatment of schizophrenia .
- 15 Sep 2020 Results comparing safety risks in clinical trials of PP3M and PP1M, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology.